ArticleFuture oncology (London, England)2025

Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US.

Jason Hafron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.